科研之友
微信
新浪微博
Facebook
分享链接
摘要
Severe mitral valve regurgitation is a serious condition with significant morbidity and mortality. It is not uncommon recently, to see patients with significant mitral valve regurgitation that are considered %26quot;non-surgical candidates%26quot; due to their comorbidities. MitraClip is a new percutaneous approach for treating mitral valve regurgitation which involves mechanical edge-to-edge coaptation of the mitral leaflets. In October of 2013, The US Food and Drug Administration (FDA) approved the MitraClip for patients with symptomatic degenerative mitral regurgitation deemed high risk for mitral-valve surgery. Several large clinical trials confirmed the safety and efficacy of MitraClip. We here discuss the growing role of MitraClip, the major clinical trials, the ongoing trials and the potential complications of the procedure.
- 出版日期2014-8
